Status:
COMPLETED
Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis
Lead Sponsor:
Swedish Orphan Biovitrum
Collaborating Sponsors:
Brigham and Women's Hospital
Harvard Medical School (HMS and HSDM)
Conditions:
Hemophagocytic Lymphohistiocytoses
Eligibility:
All Genders
18+ years
Brief Summary
This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and t...
Detailed Description
This is a observational study designed to determine the levels of pro-inflammatory markers in adult patients diagnosed with HLH and to assess the relationship between the biomarkers and disease activi...
Eligibility Criteria
Inclusion
- Patients \>=18 years old diagnosed with active HLH as established by the treating physician.
- HLH forms of unknown origin or secondary to infections or rheumatologic disorders.
- Should the diagnosis of primary HLH or malignancy become apparent after inclusion, the data collected will be analyzed separately as additional cohorts.
- The patient must have consented to the use of their clinical data for research purposes at the site.
Exclusion
- Patients with primary HLH (diagnosed by the presence of homozygous mutations in a known HLH causative gene) and secondary HLH due to malignancy are excluded.
Key Trial Info
Start Date :
December 14 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2019
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT06047210
Start Date
December 14 2016
End Date
October 30 2019
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115